William Blair analyst Margaret Kaczor has maintained their bullish stance on GKOS stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Margaret Kaczor has given her Buy rating due to a combination of factors that highlight Glaukos’s potential for long-term growth. A key element in her analysis is the promising outlook of the iDose product, which is expected to drive significant revenue growth. Despite current challenges with U.S. stent sales, the company’s strong pipeline and durable margin profile are anticipated to offset these headwinds.
Furthermore, the progress in reimbursement discussions with Medicare Administrative Contractors (MACs) is seen as a positive development. Glaukos’s management is optimistic about achieving their 2025 iDose revenue guidance without additional coverage wins, although they expect further coverage to be secured. The increasing integration of iDose procedures with cataract surgeries, free from certain restrictions, also supports the favorable long-term prospects for Glaukos.
In another report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $115.00 price target.